Yearly Licence Tolerability and Immunogenicity Study of Fluval AB Seasonal Influenza Vaccine to be Used in the 2012/2013 Vaccination Season

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
ClinicalTrials.gov Identifier:
NCT01649713
First received: July 23, 2012
Last updated: October 11, 2012
Last verified: October 2012
  Purpose

This is a yearly licence tolerability and immunogenicity study of Fluval AB suspension for injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 μgHA/strain/0.5mL) in adult and elderly subjects to assess immunogenicity of a single intramuscular injection of Fluval AB suspension for injection, as measured by haemagglutination inhibition (HI) test, and to evaluate safety and tolerability (incidence of adverse events) of a single intramuscular injection of Fluval AB suspension for injection.


Condition Intervention Phase
Influenza
Drug: Fluval AB vaccination
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Tolerability and Immunogenicity Study of Fluval AB Suspension for Injection (Trivalent, Seasonal Influenza Vaccine, Active Ingredient Content: 15 ugHA/Strain/0.5mL) in Adult and Elderly Subjects

Resource links provided by NLM:


Further study details as provided by Omninvest Vaccine Manufacturing, Researching and Trading Ltd.:

Primary Outcome Measures:
  • Assessment of immunogenicity measures in comparison to criteria specified in CPMP/BWP/214/96 [ Time Frame: 21-28 days after immunization ] [ Designated as safety issue: No ]
    To assess immunogenicity of a single intramuscular injection of Fluval AB suspension for injection (trivalent, seasonal influenza vaccine, active ingredient content: 15 μgHA/0.5mL of seasonal A/H1N1, A/H3N2 and B influenza antigens each), as measured by haemagglutination inhibition (HI) test in comparison to criteria specified in CPMP/BWP/214/96.


Secondary Outcome Measures:
  • To evaluate safety and tolerability (incidence of adverse events) of a single intramuscular injection of Fluval AB suspension for injection. [ Time Frame: From Day 0 until 21-28 days after immunization ] [ Designated as safety issue: Yes ]

    Safety and tolerability will be assessed in comparison to available safety and tolerability data on Fluval AB suspension for injection:

    • number and percentage of subjects with at least one local reaction between Day 0 and Day 21-28.
    • number and percentage of subjects with at least one systemic reaction between Day 0 and Day 21-28.
    • number and percentage of subjects with at least one adverse reaction between Day 0 and Day 21-28.


Enrollment: 120
Study Start Date: August 2012
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Fluval AB vaccination
In this uncontrolled, open, multi-centre immunogenicity and tolerability study subjects will be enrolled into one vaccination group and will be vaccinated by a single injection of Fluval AB suspension for injection.
Drug: Fluval AB vaccination
Vaccination with Fluval AB suspension for injection

Detailed Description:

For the 2011-2012 vaccination season the following influenza virus strains were recommended to be included in the influenza vaccines:

  • A/California/7/2009(H1N1)-like virus,
  • A/Perth/16/2009(H3N2)-like virus,
  • B/Brisbane/60/2008-like virus.

For the 2012-2013 season the following strains were recommended (Amended EU Recommendations for the Seasonal Influenza Vaccine Composition for the Season 2012/2013, EMA/CHMP/BWP/140597/2012):

  • A/California/7/2009(H1N1)-like virus,
  • A/Victoria/361/2011(H3N2)-like virus,
  • B/Wisconsin/1/2010-like virus.

Since the A/H3N2 and the B virus strains were changed, a yearly licence clinical study have to be performed.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Adult persons aged 18 to 59 years, elderly persons aged ≥60 years from both sexes, mentally competent;
  • Are in good health (as determined by vital signs and existing medical condition) or are in stable medical condition. Subjects will not be excluded with known adequately treated clinically significant organ or systemic diseases (e.g. asthma or diabetes), such that, in the opinion of the investigator, the significance of the disease will not compromise the subject's participation in the study;
  • Female volunteers aged 18-59 years (i.e. participants of childbearing potential) with a negative result from the urine pregnancy test prior to vaccination who agrees to use an acceptable contraception method or abstinence throughout the trial and not become pregnant for the duration of the study.
  • Capability of participants to understand and comply with planned study procedures;
  • Participants provide written informed consent prior to initiation of study procedures;
  • Absence of existence of any exclusion criteria.

Exclusion Criteria:

  • Pregnancy, breast feeding or positive urine pregnancy test at baseline prior to vaccination. Female subjects who are able to bear children but not willing to use an acceptable contraception method for the duration of the study.
  • Known hypersensitivity to eggs, chicken protein, thiomersal, formaldehyde, gentamycin, ciprofloxacin, neomycin, vancomycin or any other component of the vaccine;
  • History of Guillain-Barré syndrome;
  • History of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine;
  • Serious disease, such as cancer, autoimmune disease, advanced arteriosclerotic disease, complicated diabetes mellitus, acute or progressive hepatic disease, acute or progressive renal disease, congestive heart failure;
  • Immunosuppressive therapy within 36 months prior to vaccination;
  • Concomitant corticosteroid therapy, including high-dose inhaled corticosteroids;
  • Receipt of immunostimulants;
  • Receipt of parenteral immunoglobulin, blood products and/or plasma derivate within 3 months prior to vaccination;
  • Suspected or known HIV, HBV or HCV infection;
  • Acute disease and/or axillary temperature ≥37oC within 3 days prior to vaccination;
  • Vaccine therapy within 4 weeks prior to vaccination;
  • Influenza vaccination (any kind) within 6 months prior to vaccination;
  • Experimental drug therapy within 4 weeks prior to vaccination;
  • Concomitant participation in another clinical study;
  • Any condition which, in the opinion of the investigator, may interfere with the evaluation of the study;
  • Past or current psychiatric disease of the volunteer that upon judgement of the investigator may have effect on the objective decision-making of the volunteer;
  • Alcohol or drug abuse of the participant.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01649713

Locations
Hungary
District Doctor's Office
Budapest, Hungary, H-1083
District Doctor's Office
Pilisvörösvar, Hungary, H-2085
District Doctor's Office
Szentendre, Hungary, H-2000
Sponsors and Collaborators
Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
Investigators
Study Director: Brigitta Kozma, MD Omninvest Ltd.
Principal Investigator: Ferenc Tamás, MD District Doctor's Office, Pilisvörösvar, Hungary
  More Information

No publications provided

Responsible Party: Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
ClinicalTrials.gov Identifier: NCT01649713     History of Changes
Other Study ID Numbers: Fluval AB-H-YL2012, 2012-002379-32
Study First Received: July 23, 2012
Last Updated: October 11, 2012
Health Authority: Hungary: National Institute of Pharmacy

Keywords provided by Omninvest Vaccine Manufacturing, Researching and Trading Ltd.:
Fluval AB
influenza
vaccine
immunization
infections

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 28, 2014